Amazon jumps 5% after AWS and OpenAI announce $38B partnership
WALTHAM, Mass. - On Tuesday, Repligen Corporation (NASDAQ:RGEN) reported third-quarter results that exceeded analyst expectations, driven by broad-based growth across all business segments.
The bioprocessing technology company’s shares gained 3.11% in pre-market trading after the results.
The company posted adjusted earnings of $0.46 per share for the third quarter, beating the analyst consensus of $0.42. Revenue jumped 22% YoY to $189 million, surpassing the consensus estimate of $181.78 million. Organic revenue growth was 18% with no COVID-related revenue in the period. Compared to the same quarter last year, all franchises posted double-digit revenue growth.
"We had another outstanding quarter in Q3 with 18% organic growth," said Olivier Loeillot, President and Chief Executive Officer of Repligen. "We are thrilled with the momentum we are seeing across our broad, differentiated portfolio and the continued execution by our team."
The strong performance was broad-based, with consumables and capital equipment revenues both growing over 20%. The company reported double-digit growth across all franchises and geographies, with Asia Pacific leading regional performance. Both CDMO and biopharma revenues increased more than 20%.
Based on the strong results, Repligen raised its full-year 2025 guidance. The company now expects revenue between $729 million and $737 million, representing 14%-15.5% YoY non-COVID organic growth. This outlook exceeds the previous analyst consensus of $727.8 million. For earnings, Repligen projects adjusted EPS of $1.65-$1.68, slightly below the consensus of $1.69.
The company’s adjusted EBITDA margin was 19.0% for the quarter, compared to 20.7% in the same period last year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.